Alessi DR - Search Results

1

Crystal structure of the WD40 domain dimer of LRRK2.

Zhang P, Fan Y, Ru H, Wang L, Magupalli VG, Taylor SS, Alessi DR, Wu H. Zhang P, et al. Among authors: alessi dr. Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1579-1584. doi: 10.1073/pnas.1817889116. Epub 2019 Jan 11. Proc Natl Acad Sci U S A. 2019. PMID: 30635421 Free PMC article.

2

High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site.

Biondi RM, Komander D, Thomas CC, Lizcano JM, Deak M, Alessi DR, van Aalten DM. Biondi RM, et al. Among authors: alessi dr. EMBO J. 2002 Aug 15;21(16):4219-28. doi: 10.1093/emboj/cdf437. EMBO J. 2002. PMID: 12169624 Free PMC article.

3

LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.

Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR. Jaleel M, et al. Among authors: alessi dr. Biochem J. 2007 Jul 15;405(2):307-17. doi: 10.1042/BJ20070209. Biochem J. 2007. PMID: 17447891 Free PMC article.

4

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.

Nichols RJ, Dzamko N, Hutti JE, Cantley LC, Deak M, Moran J, Bamborough P, Reith AD, Alessi DR. Nichols RJ, et al. Among authors: alessi dr. Biochem J. 2009 Oct 23;424(1):47-60. doi: 10.1042/BJ20091035. Biochem J. 2009. PMID: 19740074 Free PMC article.

5

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.

Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, Ordureau A, Macartney T, Tong Y, Shen J, Prescott AR, Alessi DR. Nichols RJ, et al. Among authors: alessi dr. Biochem J. 2010 Sep 15;430(3):393-404. doi: 10.1042/BJ20100483. Biochem J. 2010. PMID: 20642453 Free PMC article.

6

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.

Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ. Dzamko N, et al. Among authors: alessi dr. Biochem J. 2010 Sep 15;430(3):405-13. doi: 10.1042/BJ20100784. Biochem J. 2010. PMID: 20659021 Free PMC article.

7

Uncoupling the Warburg effect from cancer.

Najafov A, Alessi DR. Najafov A, et al. Among authors: alessi dr. Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19135-6. doi: 10.1073/pnas.1014047107. Epub 2010 Nov 1. Proc Natl Acad Sci U S A. 2010. PMID: 21041650 Free PMC article. No abstract available.

8

Characterization of TAE684 as a potent LRRK2 kinase inhibitor.

Zhang J, Deng X, Choi HG, Alessi DR, Gray NS. Zhang J, et al. Among authors: alessi dr. Bioorg Med Chem Lett. 2012 Mar 1;22(5):1864-9. doi: 10.1016/j.bmcl.2012.01.084. Epub 2012 Jan 28. Bioorg Med Chem Lett. 2012. PMID: 22335897 Free PMC article.

9

The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.

Dzamko N, Inesta-Vaquera F, Zhang J, Xie C, Cai H, Arthur S, Tan L, Choi H, Gray N, Cohen P, Pedrioli P, Clark K, Alessi DR. Dzamko N, et al. Among authors: alessi dr. PLoS One. 2012;7(6):e39132. doi: 10.1371/journal.pone.0039132. Epub 2012 Jun 18. PLoS One. 2012. PMID: 22723946 Free PMC article.

10

Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.

Davies P, Hinkle KM, Sukar NN, Sepulveda B, Mesias R, Serrano G, Alessi DR, Beach TG, Benson DL, White CL, Cowell RM, Das SS, West AB, Melrose HL. Davies P, et al. Among authors: alessi dr. Biochem J. 2013 Jul 1;453(1):101-13. doi: 10.1042/BJ20121742. Biochem J. 2013. PMID: 23560750 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

310 results

Search Page